Please assess the completion status of the following clinical trial:

Trial Title: Determining Safety and Efficacy of Japanese Encephalitis Vaccine When Given With Measles Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Participant is healthy, aged between 8 months (± 2 weeks) at inclusion visit~* Subject is a full-term infant~* Subject's parents or legal guardian willing to provide signed informed consent.~* Children have completed 3 doses each of diphtheria, tetanus, pertussis (DTP) and oral polio vaccine (OPV).~Exclusion Criteria:~* History of documented HIV.~* Known or suspected impairment of immunologic function.~* History of serious chronic disease~* Underlying medical condition such as inborn errors of metabolism, failure to thrive, bronchopulmonary dysplasia, or any major congenital abnormalities requiring surgery or chronic treatment.~* Acute medical illness with or without fever within the last 72 hours or an axillary temperature ≥ 37.5°C at the time of inclusion.~* History of documented suspected encephalitis, encephalopathy, or meningitis~* History of measles~* History of thrombocytopenic purpura.~* Received any JE or measles vaccine prior to enrollment.~* Received any vaccine, other than the study vaccines, within 2 weeks prior to or scheduled to receive a non-study vaccination during the conduct of this trial.~* Hypotonic - hyporesponsiveness, after the preceding vaccination.~* History of seizures, including history of febrile seizures, or any other neurologic disorder.~* Prior or anticipated receipt of immune globulin or other blood products, or injected or oral corticosteroids or other immune modulator therapy except routine vaccines within 6 weeks of administration of the study vaccines. Individuals on a tapering dose schedule of oral steroids lasting \<7 days may be included in the trial as long as they have not received more than one course within the last 2 weeks prior to enrollment.~* Suspected or known hypersensitivity to any of the investigational or marketed vaccine components.~* Serious adverse event related to the vaccine (i.e., possible, probably, definite)~* Persistent inconsolable crying (\>3 hours) observed after a previous dose.~* Unable to attend the scheduled visits or comply with the study procedures.~* Enrolled in another clinical trial involving any therapy.~* Any condition that in the opinion of the investigator, would pose a health risk to the participant, or interfere with the evaluation of the study objectives.

- Gender: ALL
- Minimum Age: 8 Months
- Maximum Age: 11 Months
- Healthy Volunteers: t

Study Arms:
- LJEV then MV (Type: EXPERIMENTAL): Received one dose of Live Japanese encephalitis vaccine SA 14-14-2 (LJEV) at 8 months of age, and one dose of measles vaccine (MV) one month later.
- LJEV and MV (Type: EXPERIMENTAL): Received one dose of Live Japanese encephalitis vaccine SA 14-14-2 (LJEV) concurrently with one dose of measles vaccine (MV) at 9 months of age.
- MV then LJEV (Type: EXPERIMENTAL): Received one dose of measles vaccine (MV) at 9 months of age, followed by one dose of Live Japanese encephalitis vaccine SA 14-14-2 (LJEV) one month later.

Based on this trial design, predict the completion outcome and termination type (if applicable).